First Patient in Colorado Receives New Therapy for Delay of T1D Onset at the BDC
New Therapy First to Target Type 1 Diabetes Disease Process
Apr 17, 2023
For more information on screening and onset of T1D, see Ask the Experts, a program run by the BDC.
Tzield, which was approved by the FDA in 2022, is the first drug on the market indicated to delay the full onset of Type 1 Diabetes. This novel drug is available for patients in Stage-2 Type 1 Diabetes as a 1-day infusion series. As part of its ongoing commitment diabetes treatment and prevention, the Barbara Davis Center was the first site in Colorado to infuse a patient with Tzield. The Center's new Early T1D Clinic now offer this therapy in addition to screening, monitoring, long-term follow-up, and education as patients navigate the onset of T1D.
Full Story
Dr. Garg Discusses Lower Insulin Prices on CBS News Colorado.
He says it's "high time" insulin prices are lowered
Mar 1, 2023
Dr. Garg joined CBS Colorado to discuss insulin prices and why it's time manufacturers work on driving down prices.
Watch the Video
Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial
Does near normalization of glucose levels preserve pancreatic beta cell function in youth with newly diagnosed type 1 diabetes?
Feb 24, 2023
Author Contributions from the BDC's Gregory Forlenza, MD and Laurel Messer, PhD RN
In a randomized clinical trial including 113 youths aged 7 to 17 years with newly diagnosed type 1 diabetes, there was no significant difference in C-peptide levels measured during a mixed-meal tolerance test (a measure of pancreatic beta cell function) 52 weeks after diagnosis between intensive management and standard care groups. Mean time in the target range of 70 to 180 mg/dL, measured with continuous glucose monitoring, at 52 weeks was 78% with intensive management, which included automated insulin delivery, compared with 64% with standard care.
Full Story
Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes
Does once-daily oral verapamil preserve pancreatic beta cell function in children and adolescents with newly diagnosed type 1 diabetes?
Feb 24, 2023
Author Contributions from the BDC's Gregory Forlenza, MD and Laurel Messer, PhD RN
In a randomized clinical trial including 88 children and adolescents with newly diagnosed type 1 diabetes, C-peptide levels (a measure of pancreatic beta cell function) measured during a mixed-meal tolerance test 52 weeks after diagnosis were 30% higher with verapamil compared with placebo. The percentage of participants with a 52-week peak C-peptide level of 0.2 pmol/mL or greater was 95% in the verapamil group vs 71% in the placebo group. Verapamil had few adverse events.
Full Story
Smith Lab Hones in on B Cells Role in Diabetes
How Can the Body’s Immune Cells Cause Type 1 Diabetes?
Nov 28, 2022
Mia Smith's, DVM, PhD, interest in researching Diabetes and B cells all started with her love of animals. Her furry patients would come to the veterinary office sick from autoimmune conditions, disorders that trigger the body’s immune system to attack itself.
“Dogs can get many autoimmune disorders that are similar to humans – diabetes, lupus, autoimmune thyroid disease,”
With this in mind, Smith began researching diabetes and B cells – a type of immune cell – in search of preventative therapies for autoimmune conditions in both humans and their four-legged friends, conducting her research at the Barbara Davis Center for Diabetes.
In 2022, Dr. Smith sat down with the CU Anschutz media team to discuss B cell research and how these cells, along with genetics, impacts the onset of Type 1 Diabetes.
Full Story
Dr. Laurel Messer discusses greater engagement with diabetes care linked to lower glucose levels for young people
Greater engagement with diabetes care linked to lower glucose levels for young people
Aug 11, 2022
Read the full journal article in Diabetic Medicine.
Dr. Laurel Messer discussed the impacts on young people of feeling more engaged with their diabetes management. The findings were from a 2-week observational study of adolescents with Type 1 Diabetes that analyzed the biopsychosocial factors that could influence daily engagement with managing T1D.
Full Story
Dr. Marian Rewer's Research Suggests SARS-CoV-2 Infection Not Associated with Autoimmunity Related to T1D Development
SARS-CoV-2 Infection Not Associated with Autoimmunity Related to T1D Development
Aug 9, 2022
Read the full journal article in JAMA.
Dr Marian Rewers discussed new research that indicates a lack of association between infection with SARS-CoV-2 and development of Type 1 Diabetes. The study, which the Barbara Davis Center collaborated on, screened 50,000 youths across both Colorado and Bavaria, Germany to evaluate to potential that Covid-19 may trigger an autoimmune response that leads to development of T1D.
Full Story
Use Your Blood Glucose Meter to Help Improve Your Health
Nov 23, 2020
Our very own peds nurses Ashlee Ernst and Betsy Otten wrote this piece entitled “Use your blood glucose meter to help improve your health” published on Diatribe.
Full Story
T1GER Study Shows Benefit of Golimumab in Newly Diagnosed T1D
Nov 19, 2020
Dr. Andrea Steck and her team participated in a phase II, multicenter, randomized, placebo-controlled trial examining the effects of golimumab, a TNF-α inhibitor, in pediatric type 1 diabetes (T1D). Children and young adults with newly diagnosed T1D had better endogenous insulin production and less exogenous insulin use after taking golimumab for 52 weeks, compared with those who took placebo. Mean 4-hour C-peptide area under the curve, as well as the number of those who had a partial-remission response, were higher in those who took golimumab, compared with those who took placebo.
Full Story
Study Finds Better Glucose Control in Young People with Diabetes When Using Continuous Glucose Monitoring Devices
Jun 17, 2020
Read the full journal article on JAMA.
Continuous Glucose Monitors (CGM) are small devices that continually measure glucose levels under the skin, and transmit this information to a wireless device such as a receiver or cell phone. Two large multi-center studies recently published in the Journal of the American Medical Association (JAMA) tested if these devices improved glycemic control or reduced incidence of life-threatening low glucose levels in two very unique populations: adolescents and older adults living with type 1 diabetes. The CITY (CGM Intervention in Teens and Young Adults with type 1 diabetes) trial was a six month randomized controlled trial that showed that CGM helps adolescents and young adults manage their type 1 diabetes more effectively, compared with daily use of blood glucose finger-stick testing. The CGM users saw significant reductions in their hemoglobin A1C levels and less time spent with severe high and low blood glucose levels. Barbara Davis Center clinical and research staffs, including investigators Laurel Messer, PhD, Viral Shah, MD and Paul Wadwa, MD, were involved in the conduct of both landmark clinical trials.
Full Story
Study Finds Better Glucose Control in Older Adults with T1D Using CGM
Jun 16, 2020
Read the Journal article on JAMA.
Continuous Glucose Monitors (CGM) are small devices that continually measure glucose levels under the skin, and transmit this information to a wireless device such as a receiver or cell phone. Two large multi-center studies recently published in the Journal of the American Medical Association (JAMA) tested if these devices improved glycemic control or reduced incidence of life-threatening low glucose levels in two very unique populations: adolescents and older adults living with type 1 diabetes. Barbara Davis Center clinical and research staffs, including investigators Laurel Messer, PhD, Viral Shah, MD and Paul Wadwa, MD, were involved in the conduct of both landmark clinical trials.
Full Story
.jpg?sfvrsn=290640bb_3 "children on steps (cropped rectangle)")
